ALPHA JECT 5-3 injeksjonsvæske, emulsjon, vaksine til atlantisk laks

Not authorised

- Moritella viscosa, Inactivated
- Aeromonas salmonicida, subsp. salmonicida, Inactivated
- Aliivibrio salmonicida, Inactivated
- Vibrio anguillarum, serotype O1, Inactivated
- Vibrio anguillarum, serotype O2a, Inactivated

Product identification

Medicine name:
ALPHA JECT 5-3 injeksjonsvæske, emulsjon, vaksine til atlantisk laks

Active substance:
Moritella viscosa, Inactivated

Aeromonas salmonicida, subsp. salmonicida, Inactivated

Aliivibrio salmonicida, Inactivated

Vibrio anguillarum, serotype O1, Inactivated

Vibrio anguillarum, serotype O2a, Inactivated

Target species:
Atlantic salmon

Route of administration:
Intraperitoneal use

Product details

Active substance and strength:

Moritella viscosa, Inactivated
60.00 Relative Percentage Survival / 0.10 millilitre(s)

Aeromonas salmonicida, subsp. salmonicida, Inactivated
80.00 Relative Percentage Survival / 0.10 millilitre(s)

Aliivibrio salmonicida, Inactivated
90.00 Relative Percentage Survival / 0.10 millilitre(s)

Vibrio anguillarum, serotype O1, Inactivated
75.00 Relative Percentage Survival / 0.10 millilitre(s)

Vibrio anguillarum, serotype O2a, Inactivated
75.00 Relative Percentage Survival / 0.10 millilitre(s)

Pharmaceutical form:

Emulsion for injection

Withdrawal period by route of administration:

Intraperitoneal use:

- **Atlantic salmon**
  - Meat. 0 degree day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI10AB03

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Surrendered

Authorised in:

Iceland

Package description:

500 ml bag

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Pharmaq AS

Marketing authorisation date:
8/08/2013

Manufacturing sites for batch release:
Pharmaq AS

Responsible authority:
Icelandic Medicines Agency

Authorisation number:
IS/2/13/011/01

Date of authorisation status change:
1/05/2024

Reference member state:
Norway

Procedure number:
NO/V/0005/001

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 22/11/2021
Download

Package Leaflet

English (PDF)
Published on: 22/11/2021
Download